{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:58:05Z","timestamp":1782255485750,"version":"3.54.5"},"reference-count":54,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>Tofacitinib is used as an oral Janus-associated kinase (JAK) inhibitor acting on JAK1 and JAK3, in treating psoriatic disease. However, there is still no consensus on the optimal dosage and duration of tofacitinib. In this study, we aimed to evaluate the effects of tofacitinib in treating psoriatic disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A literature search was done utilising Cochrane library, Medline, EMBASE, Wiley Online library, Web of Science and BIOSIS Previews through December 18, 2022. We performed a meta-analysis of published original studies to assess the impact of tofacitinib in plaque psoriasis or psoriatic arthritis therapy based on seven randomised controlled trials (RCTs) involving 2,672 patients (receiving tofacitinib) and 853 controls (receiving placebo).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Compared with placebo, the treatment of 5 mg twice-daily (BID) tofacitinib for 12 weeks is sufficient to significantly alleviate the main clinical manifestations of psoriasis [\u226575% decrease in Psoriasis Area and Severity Index score (PASI 75): Risk ratio (RR)=4.38 (95% Confidence interval (CI) 2.51 to 7.64); \u226590% decrease in PASI score (PASI 90): RR=21.68 (95% CI 4.20 to 111.85); Physician\u2019s Global Assessment of \u2018clear\u2019 or \u2018almost clear\u2019 (PGA 0\/1): RR=3.93 (95%CI 3.03 to 5.09)]. Interestingly, there was no significant difference in improvement in PGA 0\/1 with 5 mg BID tofacitinib given for 16 weeks when compared with 5 mg BID tofacitinib for 12 weeks [RR=1.11 (95%CI 0.98 to 1.25)]. Additionally, the 5 mg BID tofacitinib for 16 weeks treatment schedule significantly increased the incidence of upper respiratory tract infection (URTI) [RR=1.89 (95%CI 1.06 to 3.38)] as compared to 5 mg BID tofacitinib for 12 weeks treatment schedule [RR=1.15 (95%CI 0.60 to 2.20)].<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The 5 mg BID tofacitinib for 12 weeks treatment significantly improved psoriasis without causing too many specific adverse events. This indicated that tofacitinib is an effective treatment plan for psoriatic disease by reasonably controlling dosage and dosing time.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_14_2024","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T06:48:12Z","timestamp":1726814892000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trials"],"prefix":"10.25259","volume":"91","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Sexual Medicine\/Traditional Chinese Medicine, Fifth People\u2019s Hospital of Shunde District (Longjiang Hospital of Shunde District), Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Shunde Polytechnic, Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fifth People\u2019s Hospital of Shunde District (Longjiang Hospital of Shunde District), Foshan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, The Second Clinical Medical College, Guangdong Medical University, Dongguan, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"10.25259\/IJDVL_14_2024\/ref-1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_14_2024\/ref-2","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_14_2024\/ref-3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.gene.6364351","article-title":"Psoriasis: Genetic associations and immune system changes","volume":"8","author":"Liu","year":"2007","journal-title":"Genes Immun"},{"key":"10.25259\/IJDVL_14_2024\/ref-4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.25259\/IJDVL_14_2024\/ref-5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","article-title":"The psychosocial burden of psoriasis","volume":"6","author":"Kimball","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjd.12276","article-title":"Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses","volume":"168","author":"Samarasekera","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jamadermatol.2014.3456","article-title":"Combining biologic therapies with other systemic treatments in psoriasis: Evidence-based, best-practice recommendations from the medical board of the national psoriasis foundation","volume":"151","author":"Armstrong","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.25259\/IJDVL_14_2024\/ref-10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ijms21020625","article-title":"Immunological memory of psoriatic lesions","volume":"21","author":"Owczarczyk Saczonek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.25259\/IJDVL_14_2024\/ref-11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: Findings from the national psoriasis foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3899\/jrheum.080691","article-title":"Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: A population-based study","volume":"36","author":"Wilson","year":"2009","journal-title":"J Rheumatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-14","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/jdv.13150","article-title":"Physician perspectives in the management of psoriasis and psoriatic arthritis: Results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey","volume":"29","author":"van de Kerkhof","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_14_2024\/ref-15","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_14_2024\/ref-16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_14_2024\/ref-17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1529-8019.2008.01215.x","article-title":"Psoriatic arthritis","volume":"22","author":"Gladman","year":"2009","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_14_2024\/ref-18","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.25259\/IJDVL_14_2024\/ref-19","doi-asserted-by":"publisher","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: A systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"key":"10.25259\/IJDVL_14_2024\/ref-20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1080\/1744666X.2021.1925541","article-title":"JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: A critical review of clinical trials","volume":"17","author":"Keeling","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/IJDVL_14_2024\/ref-22","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_14_2024\/ref-23","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.25259\/IJDVL_14_2024\/ref-24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ecco-jcc\/jjaa162","article-title":"The JAK1\/3 inhibitor tofacitinib suppresses T cell homing and activation in chronic intestinal inflammation","volume":"15","author":"Gerlach","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.25259\/IJDVL_14_2024\/ref-25","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci"},{"key":"10.25259\/IJDVL_14_2024\/ref-26","doi-asserted-by":"publisher","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_14_2024\/ref-29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_14_2024\/ref-30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_14_2024\/ref-31","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: A review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_14_2024\/ref-32","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.4049\/jimmunol.0804063","article-title":"JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL\/J mice","volume":"183","author":"Chang","year":"2009","journal-title":"J Immunol"},{"key":"10.25259\/IJDVL_14_2024\/ref-33","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_14_2024\/ref-34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.14695","article-title":"Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Kuo","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_14_2024\/ref-35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/IJDVL_14_2024\/ref-36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1146\/annurev-psych-010418-102803","article-title":"How to do a systematic review: A best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses","volume":"70","author":"Siddaway","year":"2019","journal-title":"Annu Rev Psychol"},{"key":"10.25259\/IJDVL_14_2024\/ref-37","doi-asserted-by":"publisher","first-page":"e2019008","DOI":"10.4178\/epih.e2019008","article-title":"Intervention meta-analysis: Application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.25259\/IJDVL_14_2024\/ref-38","doi-asserted-by":"publisher","first-page":"20f13698","DOI":"10.4088\/JCP.20f13698","article-title":"Understanding the basics of meta-analysis and how to read a forest plot: As simple as it gets","volume":"81","author":"Andrade","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.25259\/IJDVL_14_2024\/ref-39","first-page":"21","article-title":"Estimating risk and rate ratio in rare events meta-analysis with the mantel-haenszel estimator and assessing heterogeneity","author":"B\u00f6hning","year":"2022","journal-title":"Int J Biostat"},{"key":"10.25259\/IJDVL_14_2024\/ref-40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jclinepi.2020.09.045","article-title":"Key concepts in clinical epidemiology: Detecting and dealing with heterogeneity in meta-analyses","volume":"130","author":"Cordero","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.25259\/IJDVL_14_2024\/ref-41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/s0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: Its causes and consequences","volume":"53","author":"Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.25259\/IJDVL_14_2024\/ref-42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"10.25259\/IJDVL_14_2024\/ref-43","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"Bmj"},{"key":"10.25259\/IJDVL_14_2024\/ref-44","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-45","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_14_2024\/ref-46","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in the treatment of psoriasis: A phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_14_2024\/ref-47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_14_2024\/ref-48","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_14_2024\/ref-49","doi-asserted-by":"publisher","first-page":"7897263","DOI":"10.1155\/2018\/7897263","article-title":"Selective immunomodulation of inflammatory pathways in keratinocytes by the janus kinase (JAK) inhibitor tofacitinib: Implications for the employment of JAK-targeting drugs in psoriasis","volume":"2018","author":"Morelli","year":"2018","journal-title":"J Immunol Res"},{"key":"10.25259\/IJDVL_14_2024\/ref-50","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_14_2024\/ref-51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2340\/00015555-2960","article-title":"Tofacitinib represses the janus kinase-signal transducer and activators of transcription signalling pathway in keratinocytes","volume":"98","author":"Srivastava","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_14_2024\/ref-52","doi-asserted-by":"publisher","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.25259\/IJDVL_14_2024\/ref-53","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1097\/TP.0000000000001226","article-title":"Targeting JAK\/STAT signaling to prevent rejection after kidney transplantation: A reappraisal","volume":"100","author":"Baan","year":"2016","journal-title":"Transplantation"},{"key":"10.25259\/IJDVL_14_2024\/ref-54","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/rheumatology\/key250","article-title":"Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: A randomized, phase III, non-inferiority study","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology (Oxford)"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/tofacitinib-treatment-for-plaque-psoriasis-and-psoriatic-arthritis-a-meta-analysis-of-randomised-controlled-trials\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/tofacitinib-treatment-for-plaque-psoriasis-and-psoriatic-arthritis-a-meta-analysis-of-randomised-controlled-trials\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:18:19Z","timestamp":1739963899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/tofacitinib-treatment-for-plaque-psoriasis-and-psoriatic-arthritis-a-meta-analysis-of-randomised-controlled-trials\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":54,"alternative-id":["10.25259\/IJDVL_14_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_14_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"article-number":"172"}}